Agios Pharm

NASDAQ AGIO

Data sourced from

and

Download Data

Agios Pharm Days Inventory Outstanding (DIO) 3 year CAGR for the quarter ending March 31, 2024: -11.12%

Agios Pharm Days Inventory Outstanding (DIO) 3 year CAGR is -11.12% for the quarter ending March 31, 2024, a -209.95% change year over year. The days inventory outstanding ratio measures the average number of days it takes for a company to sell its inventory. It is calculated by dividing inventory by the cost of revenue and then multiplying by 365. This ratio indicates the average number of days inventory is held before being sold. A lower number of days suggests faster inventory turnover and efficient inventory management. CAGR, or the Compound Annual Growth Rate, quantifies the mean annual growth rate of an investment or financial metric over a specified time span, considering the influence of compounding. It is instrumental in determining the true annualized return on an investment.

Agios Pharm Days Inventory Outstanding (DIO) for the quarter ending March 31, 2023 was 7,493.70, a 180.08% change year over year.
Agios Pharm Days Inventory Outstanding (DIO) for the quarter ending March 31, 2022 was 2,675.59.
Agios Pharm Days Inventory Outstanding (DIO) for the quarter ending March 31, 2020 was 6,696.00, a 163.20% change year over year.

NASDAQ: AGIO

Agios Pharm

CEO	Dr. Bruce D. Car DACVP, Ph.D.
IPO Date	July 24, 2013
Location	United States
Headquarters	88 Sidney Street, Cambridge, MA, United States, 02139-4169
Employees	383
Sector	Healthcare
Industry	Biotechnology

Description

Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias. The company develops AG-946, a PK activator for treating lower-risk myelodysplastic syndrome and hemolytic anemias; and AG-181, a phenylalanine hydroxylase stabilizer for the treatment of phenylketonuria. Its preclinical product is siRNA for the treatment of polycythemia vera, a rare blood disorder. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.

Key trends